Serum Institute of India entry into adolescents COVID-19 vaccine market

29 March 2022

The Drugs Controller General of India (DCGI) has recently granted emergency use authorization for US biotech Novavax’ (Nasdaq: NVAX) protein-based COVID-19 vaccine for adolescents aged 12 to 18 years, which will be marketed by its partner Serum Institute of India (SII) under the brand name Covovax.

SII dominates India's overall COVID-19 vaccination drive with its vaccine Covishield, under an AstraZeneca (LSE: AZN) partnership). According to the Government of India Co-Win dashboard, as of March 28, 2022, Covishield accounted for 82% of the overall vaccine doses administered in the country for all age groups. India has so far administered over 1,830 million COVID-19 vaccine doses.

This move will help SII enter the adolescents' COVID-19 vaccine market in India, says data and analytics company GlobalData, according to whom, Covovax is India's fourth COVID-19 vaccine approved for adolescents aged 12 to 18 years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK